SYR-472 Open-label Study
NCT01751360 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 14
Last updated 2023-12-11
Summary
To evaluate the efficacy and safety of treatment with SYR-472 in diabetic patients.
Conditions
Interventions
- DRUG
-
SYR-472
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
General Manager · Takeda (Note: This product was divested to Teijin Pharma Limited in 2023)
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-04-01
- Primary Completion
- 2013-08-01
- Completion
- 2013-08-01
Countries
- Japan
More Related Trials
-
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus
NCT00653185 ·Status: COMPLETED ·Phase: PHASE2
-
A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322
NCT01686711 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus
NCT00763347 ·Status: TERMINATED ·Phase: PHASE2
-
Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan
NCT01263496 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan
NCT01318083 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Open-label Study of TAK-875
NCT01433419 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
NCT01294436 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan
NCT01263470 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes
NCT00857558 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
NCT02628392 ·Status: COMPLETED ·Phase: NA
-
Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan
NCT01318122 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
NCT06688123 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.
NCT00286468 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.
NCT00286429 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan
NCT01263509 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Double-blind Comparative Study of TAK-875
NCT01433393 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus
NCT01777282 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study
NCT00432679 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.
NCT00755846 ·Status: COMPLETED ·Phase: PHASE2
-
Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1816 in Healthy Subjects
NCT05330208 ·Status: TERMINATED ·Phase: PHASE1
-
Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus
NCT00286442 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Study of TAK-875
NCT01433406 ·Status: COMPLETED ·Phase: PHASE3
-
Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients
NCT01152385 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus
NCT01072331 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan
NCT01318109 ·Status: COMPLETED ·Phase: PHASE2/PHASE3